Capricor Therapeutics (CAPR): Weighing the $27 Analyst Target and What It Would Take

Key Takeaways

• The central $27 stock price target is the arithmetic mean of five current, verifiable analyst price targets, which range from $7 to $54.
• With Capricor Therapeutics (NASDAQ: CAPR) recently trading near $9.85, reaching $27 would require roughly 174% upside—a very large move.
• The wide analyst range reflects a binary outcome: whether the FDA approves the company's lead cell therapy, deramiocel, for Duchenne muscular dystrophy (DMD) cardiomyopathy.
• The strongest supporting factors are the deramiocel Biologics License Application (BLA) under review, positive HOPE-3 open-label extension data on upper limb function, and a cash balance near $238 million.
• The biggest risks are a negative 9-to-3 FDA advisory committee vote, an extended regulatory action date, the possibility of a complete response letter, and the absence of product revenue.
• For more detail, explore Major News, Today's Price Move, the Forecast, and upcoming Earnings on Tickeron's dedicated CAPR pages.
• Traders seeking a data-driven edge can also explore Trending AI Robots for automated signal monitoring.

Analyst Price Targets and Consensus View

Five current price targets with identifiable analysts and dates form the basis of this analysis. The lowest is Roth MKM's $7 (Hold, reiterated October 2026), followed by B. Riley Securities' $21 (Buy, upgraded September 14, 2026), Piper Sandler's $25 (Overweight, upgraded September 1, 2026), Cantor Fitzgerald's $28 (Buy, upgraded August 14, 2026), and the highest is Oppenheimer's $54 (Outperform, upgraded August 25, 2026). The arithmetic mean is $27.

The range is unusually wide, which is telling. Bullish firms tie their targets to the 24-month HOPE-3 open-label extension data and a refined DMD indication centered on upper limb function, with B. Riley applying a 40% probability of approval within its model. More cautious firms, including H.C. Wainwright, still describe regulatory risk as high, citing the negative advisory committee vote and open questions about the HOPE-3 dataset. This is not a normal valuation spread—it is a probability-weighted bet on a single regulatory decision. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapies for rare diseases. Its lead candidate, deramiocel (formerly CAP-1002), targets DMD cardiomyopathy. Shares recently closed near $9.85, well below the 52-week high of $40.37 but above the 52-week low of $2.96. Reaching $27 would require about 174% upside, a very large move that would effectively require the FDA approval scenario to begin being priced in.

The company has resubmitted data to the FDA after an earlier response letter, and the action date was subsequently extended. Even so, the stock has rallied from the low single digits as open-label extension data showed slower upper limb decline. Any path toward the target hinges on regulatory progress rather than near-term fundamentals, given the company currently reports no meaningful product revenue.

What Could Support a Move Toward the Target

• A positive FDA decision on the deramiocel BLA, or even a narrowed DMD indication focused on upper limb function, would materially de-risk the story.
• HOPE-3 open-label extension data showing a 76% slowing of upper limb decline in the crossover analysis supports the clinical rationale.
• Analyst upgrades from Piper Sandler, B. Riley, Cantor Fitzgerald, and Oppenheimer reflect a shift in probability-weighted valuation.
• Roughly $238 million in cash, equivalents, and marketable securities as of June 30, 2026, provides a runway through the regulatory process.
• A commercial partnership with Nippon Shinyaku for U.S. and Japan distribution establishes a launch pathway if approved.

What Could Prevent the Target From Being Reached

• The FDA advisory committee voted 9-to-3 against the current data package, and the agency extended its action date—signals that approval is far from assured.
• A complete response letter or a requirement for additional clinical data could substantially delay or derail commercialization.
• The company has no approved product and generated no product revenue as of mid-2026, leaving the valuation almost entirely dependent on a single asset.
• Multiple securities class action complaints have been filed, an additional overhang independent of the science.
• Heavy reliance on one late-stage therapy means a single negative headline can compress the stock sharply, as seen in the wide $7-to-$54 target range.

Technical Levels and Market Structure

Shares have climbed from roughly $7 in early November to near $9.85, testing the psychological $10 resistance level, with recent intraday highs around $10.00-$10.06. Nearby support sits in the $8.50-$8.60 zone, followed by the low-$7 area from early November. The 52-week high near $40.37 serves as a distant reference point, while the 52-week low near $2.96 marks the post-advisory-committee trough. The stock remains well below its longer-term moving averages, reflecting how far it fell after the regulatory setback, and any sustained move toward $27 would require a structural break above prior resistance levels.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of approximately 12 months, though individual firms do not always publish an explicit timeframe. For a pre-commercial biotech, the real drivers are event-based rather than quarterly. Investors should monitor the FDA's decision on the deramiocel BLA and any subsequent action date, the third-quarter 2026 results and corporate update (reported November 10, 2026), further HOPE-3 data presentations, cash burn relative to the roughly $238 million balance, and any additional analyst rating or target revisions. Regulatory commentary, rather than earnings alone, is the dominant variable. From what I see, tracking these catalysts with additional tools can help clarify the picture.

Using Data-Driven Signals in Volatile Names

In my view, incorporating automated monitoring into the research process adds a useful layer when following event-driven stories like this one. Tickeron's AI Daily Buy/Sell Signals provide a data-driven complement to fundamental research. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. For a volatile name like CAPR, where sentiment can shift quickly around regulatory headlines, such signals can help traders discover opportunities, monitor positions, and spot changing trends without manually reviewing every data point.

Final Assessment

The question of whether Capricor Therapeutics can reach $27 is ultimately a question about deramiocel's regulatory fate. The $27 central target—the mean of five analyst targets spanning $7 to $54—represents a probability-weighted bet on FDA approval, not a reflection of current fundamentals. The 174% move required is very large, and the negative advisory committee vote plus the extended action date are serious obstacles. Yet the supportive open-label extension data, a substantial cash runway, and a wave of analyst upgrades show why several firms assign meaningful upside. Investors should weigh the wide analyst disagreement carefully and watch the FDA decision, cash position, and clinical data flow above all else. No outcome is guaranteed.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume